Correctly identifying a product as a combination product—and understanding which type it represents—has direct consequences for regulatory strategy, lead center assignment, premarket pathway selection, and postmarket compliance obligations. Misclassification at the outset can result in submission to the wrong FDA center, gaps in safety reporting obligations, or delays that compound throughout the product lifecycle.
This analysis examines the four combination product types defined under 21 CFR 3.2(e) as restated in FDA guidance, explaining how each type is distinguished, how FDA determines the lead center through the primary mode of action framework, and what the classification means for sponsors navigating premarket and postmarket requirements.
Want Rhizome's help on your own question? Try it for free.
Combination product types: the four categories under 21 CFR 3.2(e)
What FDA means by "combination product"
A combination product is a product composed of two or more different types of medical products, that is, a combination of a drug, device, and/or biological product with one another. The individual drug, device, or biological product in the combination is called a "constituent part." 57
The regulatory taxonomy in 21 CFR 3.2(e) sorts these into four types, distinguished by how the constituent parts are physically related to each other and, for the cross-labeled categories, whether the co-used product is approved or investigational. 257
The four types
1. Single-entity combination products, 21 CFR 3.2(e)(1)
Two or more regulated components that are physically, chemically, or otherwise combined or mixed and produced as a single entity. 257 These are the "integral" products where the constituent parts are inseparable at the point of use. Examples cited by FDA include a prefilled syringe, a transdermal patch, and a drug-eluting stent. 257
2. Co-packaged combination products, 21 CFR 3.2(e)(2)
Two or more separate products packaged together in a single package or as a unit: drug and device products, device and biological products, or biological and drug products. 257 The constituent parts are distinct items shipped together rather than fused into one entity. Examples include a surgical kit or a first-aid kit. 257
3. Cross-labeled combination products, approved constituent parts, 21 CFR 3.2(e)(3)
A drug, device, or biological product packaged separately that, according to its labeling, is intended for use only with an approved, individually specified drug, device, or biological product, where both are required to achieve the intended use, indication, or effect, and where, upon approval of the proposed product, the labeling of the approved product would need to be changed. 257 FDA's example is a light-emitting device intended for use with a specific light-activated drug. 2714
4. Cross-labeled combination products, investigational constituent parts, 21 CFR 3.2(e)(4)
Any investigational drug, device, or biological product packaged separately that, according to its proposed labeling, is for use only with another individually specified investigational drug, device, or biological product, where both are required to achieve the intended use, indication, or effect. 257 This mirrors category (e)(3) but applies where both co-used constituent parts are still investigational rather than approved.
How a combination product is assigned to a lead center
Classification into one of the four types is separate from the question of which FDA center reviews the product. FDA assigns a combination product to a lead center based on which constituent part provides the product's primary mode of action (PMOA), and that lead center holds primary jurisdiction for both premarket review and postmarket regulation. 14192021
PMOA is the single mode of action (drug, device, or biological product) expected to make the greatest contribution to the combination product's overall intended therapeutic effects. In practice, FDA looks at which constituent part drives the main therapeutic effect. 14192038
- Drug-led PMOA: CDER generally has primary jurisdiction. 2831
- Biologic-led PMOA: CBER has primary jurisdiction. 1937
- Device-led PMOA: CDRH has primary jurisdiction. 1424
Regardless of which center leads, the centers coordinate with each other and with the Office of Combination Products (OCP) as appropriate. 14192021 Where the lead center is unclear or disputed, a sponsor can seek a Request for Designation (RFD) or a Pre-RFD from OCP for a formal determination. 14212941
Premarket application approaches
The four-type classification and the PMOA-based center assignment together shape how the product is submitted for review.
- In most instances, FDA can regulate the entire combination product under a single marketing application (one BLA, NDA, or PMA), which should contain all information needed to support approval of the product as a whole, including each constituent part. One investigational application (for example, a single IND) is generally sufficient as well. 3943
- Separate applications for the constituent parts are generally permissible for cross-labeled combination products, and in limited situations FDA may determine that a single application is not appropriate and that an application for each constituent part is warranted. FDA may also require, or accept upon request, two or more marketing applications. 4344
The application type is generally selected to coincide with the product's PMOA: NDA or ANDA for drug-led products, BLA for biologic-led products, and PMA, De Novo, or 510(k) for device-led products. 44 The chosen application type should permit a "substantially similar evaluation" to what would apply if the constituent parts were reviewed under separate applications; if the PMOA-based type would not allow that, FDA may direct the product to a different application type that still coincides with the PMOA, or, in limited cases, to an application type tied to the statutory authorities applicable to the non-lead constituent part. 44
Quick reference
| Type | Citation | Definition in brief | FDA examples |
|---|---|---|---|
| Single-entity | 21 CFR 3.2(e)(1) | Components physically/chemically combined and produced as one entity 257 | Prefilled syringe, transdermal patch, drug-eluting stent 257 |
| Co-packaged | 21 CFR 3.2(e)(2) | Separate products packaged together in one package/unit 257 | Surgical kit, first-aid kit 257 |
| Cross-labeled (approved) | 21 CFR 3.2(e)(3) | Separately packaged, labeled for use only with a specified approved product; both required for the effect; approved product's labeling would change 257 | Light-emitting device used with a specific light-activated drug 2714 |
| Cross-labeled (investigational) | 21 CFR 3.2(e)(4) | Separately packaged investigational product labeled for use only with another specified investigational product; both required for the effect 257 | (No specific example given in the reviewed guidances) |
Limitations
The definitions above are FDA's, as restated in guidance; the binding text is the regulation itself at 21 CFR 3.2(e). This note covers the US framework only. It does not address how the same physical products are classified in other jurisdictions, nor the detailed CGMP (21 CFR Part 4), postmarket safety reporting, human factors, or bridging expectations that attach once a product is confirmed to be a combination product. Those are natural follow-ups worth asking Rhizome about directly.